Videos Agriculture Health Business Education Positive Breaking Sports Ansuni Gatha Advertise with Us Catch The Rainnew More


COVID-19: Bharat Biotech receives DCGI approval for India's first intranasal vaccine

by Rishika Choudhury

Date & Time: Sep 06, 2022 8:00 PM

Read Time: 1 minute

The Drugs Controller General of India (DCGI) granted Bharat Biotech emergency use authorization for the Intranasal Covid-19 vaccine on September 6. This will be India's first nasal vaccine for COVID-19.

Mansukh Mandaviya, Union Minister of Health and Family Welfare, described it as a "significant boost" to India's fight against Covid-19.

He took to Twitter and said, "Big Boost to India's Fight Against COVID-19! Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation."

"This step will further strengthen our collective fight against the pandemic. India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji's leadership," he added.

He also said that we will defeat Covid-19 with a science-driven approach.

"With the science-driven approach and Sabka Prayas, we will defeat COVID-19," he said.

Also Read: Covaxin proven safe for children of 2-18 years age group in phase II/III study

You May Also Like


No Comments to show, be the first one to comment!

Leave a comment

Your email address will not be published. Required fields are marked *